DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, JA | - |
dc.contributor.author | Park, K | - |
dc.contributor.author | Jung, H | - |
dc.contributor.author | Kim, H | - |
dc.contributor.author | Hong, SW | - |
dc.contributor.author | Yoon, SK | - |
dc.contributor.author | Hahn, SK | - |
dc.date.accessioned | 2016-03-31T09:20:37Z | - |
dc.date.available | 2016-03-31T09:20:37Z | - |
dc.date.created | 2011-12-20 | - |
dc.date.issued | 2011-11 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.other | 2011-OAK-0000024398 | - |
dc.identifier.uri | https://oasis.postech.ac.kr/handle/2014.oak/17039 | - |
dc.description.abstract | Interferon alpha (IFN alpha) conjugated with polyethylene glycol (PEG) has been widely used for the treatment of hepatitis C virus (HCV) infection as a once-a-week injection formulation. However, the PEGylated IFN alpha has a low efficacy of ca. 39% and a side effect after repeated injections possibly due to the nonspecific delivery with PEGylation. In this work, target specific long-acting hyaluronic acid-interferon alpha (HA-IFN alpha) conjugate was successfully developed for the treatment of HCV infection. HA-IFN alpha conjugate was synthesized by coupling reaction between aldehyde modified HA and the N-terminal group of IFN alpha. The IFN alpha content could be controlled in the range of 2-9 molecules per single HA chain with a bioconjugation efficiency higher than 95%. According to in vitro anti-proliferation assay using Daudi cells, HA-IFN alpha conjugate showed a comparable biological activity to PEG-Intron. In vivo real-time bioimaging confirmed the target specific delivery of near-infrared fluorescence (NIRF) dye labeled HA-IFN alpha conjugate to the liver in mice. In addition, pharmacokinetic analysis revealed the enhanced residence time longer than 4 days. After tail-vein injection, HA-IFN alpha conjugate induced ca. 60% higher expression of 2',5'-oligoadenylate synthetase 1 (OAS 1) for innate immune responses to viral infection in the murine liver tissues than IFN alpha and PEG-Intron. (C) 2011 Elsevier Ltd. All rights reserved. | - |
dc.description.statementofresponsibility | X | - |
dc.language | English | - |
dc.publisher | ELSEVIER | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.subject | Hyaluronic acid | - |
dc.subject | Interferon alpha | - |
dc.subject | Conjugate | - |
dc.subject | Targeted delivery | - |
dc.subject | Hepatitis C virus | - |
dc.subject | PROTEIN | - |
dc.subject | DELIVERY | - |
dc.subject | RECEPTOR | - |
dc.subject | CD44 | - |
dc.subject | IDENTIFICATION | - |
dc.subject | PEGYLATION | - |
dc.subject | RIBAVIRIN | - |
dc.subject | PEPTIDE | - |
dc.subject | FORM | - |
dc.title | Target specific hyaluronic acid-interferon alpha conjugate for the treatment of hepatitis C virus infection | - |
dc.type | Article | - |
dc.contributor.college | 신소재공학과 | - |
dc.identifier.doi | 10.1016/J.BIOMATERIALS.2011.07.088 | - |
dc.author.google | Yang, JA | - |
dc.author.google | Park, K | - |
dc.author.google | Jung, H | - |
dc.author.google | Kim, H | - |
dc.author.google | Hong, SW | - |
dc.author.google | Yoon, SK | - |
dc.author.google | Hahn, SK | - |
dc.relation.volume | 32 | - |
dc.relation.issue | 33 | - |
dc.relation.startpage | 8722 | - |
dc.relation.lastpage | 8729 | - |
dc.contributor.id | 10149037 | - |
dc.relation.journal | BIOMATERIALS | - |
dc.relation.index | SCI급, SCOPUS 등재논문 | - |
dc.relation.sci | SCI | - |
dc.collections.name | Journal Papers | - |
dc.type.rims | ART | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, v.32, no.33, pp.8722 - 8729 | - |
dc.identifier.wosid | 000295858700040 | - |
dc.date.tcdate | 2019-01-01 | - |
dc.citation.endPage | 8729 | - |
dc.citation.number | 33 | - |
dc.citation.startPage | 8722 | - |
dc.citation.title | BIOMATERIALS | - |
dc.citation.volume | 32 | - |
dc.contributor.affiliatedAuthor | Hahn, SK | - |
dc.identifier.scopusid | 2-s2.0-80052963561 | - |
dc.description.journalClass | 1 | - |
dc.description.journalClass | 1 | - |
dc.description.wostc | 31 | - |
dc.description.scptc | 30 | * |
dc.date.scptcdate | 2018-05-121 | * |
dc.type.docType | Article | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | CD44 | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | RIBAVIRIN | - |
dc.subject.keywordPlus | PEPTIDE | - |
dc.subject.keywordPlus | FORM | - |
dc.subject.keywordAuthor | Hyaluronic acid | - |
dc.subject.keywordAuthor | Interferon alpha | - |
dc.subject.keywordAuthor | Conjugate | - |
dc.subject.keywordAuthor | Targeted delivery | - |
dc.subject.keywordAuthor | Hepatitis C virus | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
library@postech.ac.kr Tel: 054-279-2548
Copyrights © by 2017 Pohang University of Science ad Technology All right reserved.